Note 18 - Supplementary Financial Information (unaudited) (Tables)

3 Months Ended

Mar. 31, 2013

Schedule of Quarterly Financial Information [Table Text Block]

(in $000’s except shares and per share amounts)	Quarter Ended: March 31, 2013
Revenue:
Global Product sales, gross	$	197,956
Less:
Chargebacks		64,345
Rebates		30,572
Product Returns		94
Other credits		5,160
Global Product sales, net		97,785
Rx Partner		3,114
Other Revenues		737
Global Division revenues, net		101,636
Impax Product sales, gross		69,292
Less:
Chargebacks		7,790
Rebates		6,236
Product Returns		1,490
Other credits		7,255
Impax Product sales, net		46,521
Other Revenues		332
Impax Division revenues, net		46,853
Total revenues		148,489
Gross profit		57,871
Net income	$	105,442
Net income per share (basic)	$	1.59
Net income per share (diluted)	$	1.55
Weighted Average:
common shares outstanding:
Basic		66,487,470
Diluted		68,178,355

(in $000’s except shares and per share amounts)	Quarter Ended: March 31, 2012
Revenue:
Global Product sales, gross	$	185,671
Less:
Chargebacks		39,155
Rebates		20,589
Product Returns		(329	)
Other credits		10,045
Global Product sales, net		116,211
Rx Partner		2,978
Other Revenues		4,076
Global Division revenues, net		123,265
Impax Product sales, gross		--
Less:
Chargebacks		--
Rebates		--
Product Returns		--
Other credits		--
Impax Product sales, net		--
Other Revenues		5,303
Impax Division revenues, net		5,303
Total revenues		128,568
Gross profit		62,553
Net income	$	12,365
Net income per share (basic)	$	0.19
Net income per share (diluted)	$	0.18
Weighted Average:
common shares outstanding:
Basic		65,122,240
Diluted		67,907,263